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Short Communication
Inhibition of mammary carcinogenesis by flurbiprofen,
a non-steroidal antiinflammatory agent
D.L. McCormick & R.C. Moon
Laboratory ofPathophysiology, IIT Research Institute, Chicago, IL 60616 U.S.A.
The phenylalkanoic acid derivative, flurbiprofen (2-
[2-fluoro-4-biphenylyl]propionic acid), is a non-
steroidal drug with antiinflammatory, antipyretic,
and analgesic properties. The biological activity of
flurbiprofen appears to be based on its activity as a
modifier of arachidonic acid metabolism, resulting
in a significant inhibition of prostaglandin (PG)
biosynthesis. Studies in a variety of in vivo and in
vitro systems have found flurbiprofen to be 2-20
times more potent than indomethacin in inhibiting
PGE2 production (Brogden et al., 1979; Boots,
1981).
Flurbiprofen inhibits PG biosynthesis by
inhibiting the cyclooxygenase component of PG
synthetase (Nozu, 1978); this enzyme catalyzes the
transformation of arachidonic acid into PG
endoperoxides, which are then further metabolized
to form PGs and thromboxanes. However, limited
evidence suggests that flurbiprofen may also inhibit
the lipoxygenase pathway of arachidonic acid
metabolism (Higgs et al., 1980); lipoxygenase is not
involved in PG synthesis, but does modulate the
production of leukotrienes and hydroperoxy and
hydroxy fatty acids.
Previous studies have shown that flurbiprofen
has significant therapeutic activity when
administered to animals bearing transplantable
tumours. In studies with the NC mammary
adenocarcinoma, Bennett and colleagues
demonstrated that administration of flurbiprofen
can both inhibit the growth ofprimary transplanted
tumours (Leaper et al., 1979), and increase mean
survival time in mice following resection of the
primary lesion (Bennett et al., 1982). In the same
model system, flurbiprofen enhanced the chemo-
therapeutic activity of methotrexate or melphalan
(Berstock et al., 1979; Bennett et al., 1982). Powles
et al. (1978) have reported a similar enhancement
of chlorambucil activity against a chemotherapy-
resistant variant ofthe Walker tumour.
We have recently reported that the PG synthesis
inhibitor indomethacin has significant activity in
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inhibiting chemically-induced mammary
carcinogenesis in rats (McCormick & Moon,
1983b). The present study was performed to
determine if, in addition to its therapeutic activity
against established tumours, flurbiprofen can also
inhibit mammary carcinogenesis when administered
prior to tumour appearance.
Mammary carcinomas were induced in female
Sprague-Dawley rats by a single injection of N-
methyl-N-nitrosourea (MNU) as previously
described in detail (McCormick et al., 1981).
Crystalline MNU (Ash-Stevens, Detroit, MI) was
dissolved in sterile saline solution (pH 5.0)
immediately prior to use. At 50 days of age, rats
were lightly anaesthesized with ether and received a
single injection of 50mg or 25mg MNU per kg
body weight via the jugular vein. Control animals
received an injection ofsterile saline solution only.
One week after MNU administration, animals
were randomized into experimental groups by
weight (Table I). At this time, administration of
control diet (Wayne Lab Meal, Allied Mills,
Chicago, IL), or control diet supplemented with
62.5 or 31.25mg flurbiprofen kg-l diet was begun.
Flurbiprofen was a generous gift of Dr. Paul
Bresloff, Boots Co., Ltd., Nottingham; dose levels
of flurbiprofen were chosen to provide a dose of
approximately 5.0 or 2.5mgkg-1 body wt per day.
Beginning 4 weeks after MNU administration,
animals were palpated twice weekly to monitor
mammary tumour appearance. Animals were
observed twice daily and weighed weekly
throughout the study. At 180 days after MNU
administration, the experiment was terminated and
all animals were killed by CO2 asphyxiation. All
mammary tumours and any other grossly abnormal
tissues were removed and prepared for histopatho-
logical classification. Only histologically-confirmed
mammary cancers (adenocarcinomas and papillary
carcinomas) were used in the data analysis.
Intravenous administration of MNU induced
mammary cancers in a dose-related manner. In
group 3, which received a dose of 50mg MNU
kg- I body wt and the control diet, the first
mammary tumour became palpable at 36 days after
carcinogen administration; cancer incidence reached
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Table I Influence offlurbiprofen on mammary carcinogenesis induced by MNU
At 180 days
No. of MNU dose Flurbiprofen dose Tso Cancer incidence Carcinomas Body wt
Group animals (mgkg body weight) (mgkg-I diet) (days) (%) per rat (±s.e.)
1 15 Saline 0 0 0 283+6
2 15 Saline 62.5 0 0 289+5
3 30 50 0 67 100 6.21 283+4
4 30 50 31.25 60 100 6.09 276+4
5 30 50 62.5 70 100 6.20 292+ 10
6 30 25 0 112 91 2.23 291 +6
7 30 25 31.25 130 60** 1.38** 283+4
8 30 25 62.5 133 68* 1.53** 287+4
*P<0.10Ovs group 6.
**P<0.05 vs group 6.
Note: Cancer incidence and carcinomas per rat were calculated using the lifetable method. Statistical tests
used: incidence, logrank test; body weight, analysis of variance; carcinomas per rat, analysis of variance;
median cancer induction time (T0), median test.
50% by 67 days, and was 100% at 97 days post-
MNU. In group 6, which received the 25mg MNU
kg-1 dose and the control diet, the first palpable
mammary lesion appeared at 60 days, and a 50%
cancer incidence was reached at 112 days after
MNU administration. In addition to increased
incidence with a shorter tumour latent period, the
high MNU dose induced -3 times as many cancers
per rat as did the low MNU dose (Table I).
The influence of flurbiprofen on mammary
carcinogenesis was a function of carcinogen dose.
At the high MNU dose, flurbiprofen had no
activity as an inhibitor of carcinogenesis in terms of
cancer incidence, carcinoma multiplicity, or tumour
latent period. Final cancer incidence was 100% in
all groups receiving 50mg MNU kg-1, regardless
of the presence or absence of the flurbiprofen
dietary supplement. Similarly, all groups had -6.2
mammary cancers per animal. No effect of
flurbiprofen on tumour latency was found at this
MNU dose: time to 50% cancer incidence (T50) was
67 days in the control group, and 60 and 70 days in
the low and high flurbiprofen groups, respectively.
By contrast, flurbiprofen had significant activity
as an inhibitor of mammary carcinogenesis induced
by the low dose of MNU. Administration of
flurbiprofen at both 62.5 and 31.25mgkg-1 diet
dose levels reduced mammary carcinoma
multiplicity by 1/3 compared to control
(P<0.05). Cancer incidence was also influenced by
flurbiprofen treatment, as incidence was reduced
from 91% in the diet control group to 60 and 68%
in the two flurbiprofen groups. Although a trend
towards increased median tumour latency was
observed with flurbiprofen administration
(T50= 112 days in the control group versus 130 and
133 days in flurbiprofen groups), this increase was
not statistically significant.
The reasons for the effect of carcinogen dose on
the chemopreventive activity of flurbiprofen are
unknown. Little data exist to suggest a differential
biology for tumours of the same histological type
induced by different doses of carcinogen, although
Rose et al. (1980) have reported that mammary
cancers induced by a high dose MNU regimen (3
doses of 50mgkg-1) are less sensitive to oestrogen
withdrawal than are cancers induced by a lower
total MNU dose (2 doses of 50mgkg-1). Thus, the
possibility does exist that tumours with a short
latent period may be less responsive to modulation,
in effect "overwhelming" the influence of the
modifier. Support for such a view comes from
our studies with indomethacin. In animals treated
with a dose of carcinogen (8mg 7,12-
dimethylbenz(a)anthracene, DMBA) comparable to
the low dose of MNU used in this study, two dose
levels of indomethacin both inhibited mammary
cancer induction. By contrast, at a carcinogen dose
(16mg DMBA) comparable to the high dose of
MNU, the low indomethacin dose had no effect on
cancer response, while the high dose retained its
anticarcinogenic efficacy (McCormick & Moon,
1983b; McCormick, unpublished).
Flurbiprofen inhibited mammary carcinogenesis
without toxicity. As indicated in Table I, neither
dose level of flurbiprofen had any effect on animal
body wt gain ovex the course of the study. No
evidence of gastrointestinal or renal toxicity was
observed at necropsy in any experimental group.
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inhibitors of arachidonic acid metabolism such as
flurbiprofen is consistent with studies performed in
other experimental tumour models, notably mouse
skin -and rat colon (Verma et al., 1980; Pollard &
Luckert, 1981; Narisawa et al., 1981). The
mechanism(s) by which these agents inhibit cancer
induction are unknown, although influences on cell
kinetics (Bayer et al., 1979; Boynton & Whitfield,
1980), mammary gland differentiation (Miyamoto-
Tiaven et al., 1981; McCormick & Moon, 1983b),
and immune function (Droller et al., 1978; Glaser,
1980) may be involved.
These data indicate that modulation of arachi-
donic acid metabolism is a mechanism through
which mammary carcinogenesis can be inhibited in
experimental animals. Further study is required to
determine the role of specific eicosanoids (PGs,
thromboxanes, leukotrienes, and hydroperoxy and
hydroxy fatty acids) in mammary cancer induction,
and to elucidate the mechanisms by which
modification of arachidonic acid metabolism
inhibits carcinogenesis.
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